Apologizes J-Bo,
Sorry I didn't answer your request, I only now read your post. Hope you were able to find the entire article ok.
The conclusion was most interesting to me. Presuming most of the 22,000 HIV positive were on HAART (highly active antiretroviral therapy) and finding the incidence of MS in HIV+ was about 1/4th of the rate in millions of those not HIV positive is notable. That could be due to the antiretroviral.
A monoclonal antibody thus far called GNbAC1 was developed to act against MSRV ( multiple sclerosis- associated retrovirus). This small trial tested for safety. It is interesting that human research involving antiretroviral treatments for MS now has two substances, Raltegravir (Isentress) and GNbAC1.
GNbAC1, a Humanized Monoclonal Antibody Against the Envelope Protein of Multiple Sclerosis—Associated Endogenous Retrovirus: A First-in-Humans Randomized Clinical Study
http://www.clinicaltherapeutics.com/...12)00649-2/pdf
Sorry I didn't answer your request, I only now read your post. Hope you were able to find the entire article ok.
The conclusion was most interesting to me. Presuming most of the 22,000 HIV positive were on HAART (highly active antiretroviral therapy) and finding the incidence of MS in HIV+ was about 1/4th of the rate in millions of those not HIV positive is notable. That could be due to the antiretroviral.
A monoclonal antibody thus far called GNbAC1 was developed to act against MSRV ( multiple sclerosis- associated retrovirus). This small trial tested for safety. It is interesting that human research involving antiretroviral treatments for MS now has two substances, Raltegravir (Isentress) and GNbAC1.
GNbAC1, a Humanized Monoclonal Antibody Against the Envelope Protein of Multiple Sclerosis—Associated Endogenous Retrovirus: A First-in-Humans Randomized Clinical Study
http://www.clinicaltherapeutics.com/...12)00649-2/pdf
Comment